Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
Authors
Keywords
-
Journal
Pharmaceutics
Volume 12, Issue 10, Pages 939
Publisher
MDPI AG
Online
2020-09-30
DOI
10.3390/pharmaceutics12100939
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis
- (2020) Xinmin Zeng et al. Aging-US
- Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer
- (2020) Xinyou Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
- (2020) Jiyun Lee et al. Journal of Thoracic Oncology
- Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
- (2019) Patrick R. Halliday et al. Current Oncology Reports
- Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance
- (2019) Meng Lei et al. DRUG DELIVERY
- Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
- (2019) Xiaoyan Lu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Prevention of paclitaxel-induced neuropathy by formulation approach
- (2019) Xiaowei Zang et al. JOURNAL OF CONTROLLED RELEASE
- Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma
- (2019) Sushant Lakkadwala et al. JOURNAL OF CONTROLLED RELEASE
- LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
- (2019) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
- (2019) Daisuke Hayakawa et al. Thoracic Cancer
- Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
- (2019) James C.H. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of liposomes in clinical nanomedicine development. What now? Now what?
- (2019) Daan J.A. Crommelin et al. JOURNAL OF CONTROLLED RELEASE
- A novel pH-sensitive liposome to trigger delivery of afatinib to cancer cells: Impact on lung cancer therapy
- (2018) Alanood S. Almurshedi et al. JOURNAL OF MOLECULAR LIQUIDS
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract CT013: Osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with11C-labelled osimertinib
- (2018) Karthick Vishwanathan et al. CANCER RESEARCH
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug nanocrystallisation within liposomes
- (2018) Tang Li et al. JOURNAL OF CONTROLLED RELEASE
- Systems analysis of intracellular pH vulnerabilities for cancer therapy
- (2018) Erez Persi et al. Nature Communications
- Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
- (2018) Nannan Wang et al. ONCOLOGY REPORTS
- Review – An update on the use of oral phospholipid excipients
- (2017) Peter van Hoogevest EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- The significance of drug-to-lipid ratio to the development of optimized liposomal formulation
- (2017) Maria Chountoulesi et al. JOURNAL OF LIPOSOME RESEARCH
- Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation
- (2017) Xiao Zhou et al. Drug Design Development and Therapy
- Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations
- (2017) Haoping Xu et al. Artificial Cells Nanomedicine and Biotechnology
- Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma
- (2016) Matthew J. Martin et al. Oncotarget
- New Developments in Liposomal Drug Delivery
- (2015) Bhushan S. Pattni et al. CHEMICAL REVIEWS
- Lung Cancer in the Era of Precision Medicine
- (2015) K. Politi et al. CLINICAL CANCER RESEARCH
- Nanotechnology approaches for inhalation treatment of lung diseases
- (2015) Andriy Kuzmov et al. JOURNAL OF CONTROLLED RELEASE
- Mathematical models in drug delivery: How modeling has shaped the way we design new drug delivery systems
- (2014) Nicholas A. Peppas et al. JOURNAL OF CONTROLLED RELEASE
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes
- (2013) Xin Liu et al. Asian Journal of Pharmaceutical Sciences
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
- (2012) Jeffrey A. Silverman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method
- (2012) Koji Nakamura et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride
- (2012) Sandy Vrignaud et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- Physicochemical Properties of Epidermal Growth Factor Receptor Inhibitors and Development of a Nanoliposomal Formulation of Gefitinib
- (2012) Brian J. Trummer et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B
- (2011) Alexander Koshkaryev et al. JOURNAL OF DRUG TARGETING
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles
- (2010) Yong Zhang et al. AAPS Journal
- Endocytosis of nanomedicines
- (2010) Gaurav Sahay et al. JOURNAL OF CONTROLLED RELEASE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance
- (2010) O. B. Garbuzenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents
- (2009) Gaurav Sahay et al. BIOMATERIALS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started